Noile-Immune Biotech Inc.

TSE:4893 Stock Report

Market Cap: JP¥6.8b

Noile-Immune Biotech Balance Sheet Health

Financial Health criteria checks 6/6

Noile-Immune Biotech has a total shareholder equity of ¥4.9B and total debt of ¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ¥5.0B and ¥68.0M respectively.

Key information

0%

Debt to equity ratio

JP¥0

Debt

Interest coverage ration/a
CashJP¥4.72b
EquityJP¥4.90b
Total liabilitiesJP¥68.00m
Total assetsJP¥4.97b

Recent financial health updates

Recent updates

We're Not Very Worried About Noile-Immune Biotech's (TSE:4893) Cash Burn Rate

Sep 17
We're Not Very Worried About Noile-Immune Biotech's (TSE:4893) Cash Burn Rate

Here's Why We're Not Too Worried About Noile-Immune Biotech's (TSE:4893) Cash Burn Situation

Apr 17
Here's Why We're Not Too Worried About Noile-Immune Biotech's (TSE:4893) Cash Burn Situation

Financial Position Analysis

Short Term Liabilities: 4893's short term assets (¥4.9B) exceed its short term liabilities (¥62.0M).

Long Term Liabilities: 4893's short term assets (¥4.9B) exceed its long term liabilities (¥6.0M).


Debt to Equity History and Analysis

Debt Level: 4893 is debt free.

Reducing Debt: 4893 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4893 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 4893 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 22.1% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 07:42
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Noile-Immune Biotech Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stephen BarkerJefferies LLC
Miyabi YamakitaJefferies LLC